Gain Therapeutics, Inc. (NASDAQ:GANX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Gain Therapeutics, Inc. (NASDAQ:GANX) has been given an average recommendation of “Moderate Buy” by the six ratings firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $8.00.

A number of research analysts have commented on the stock. Roth Mkm reissued a “buy” rating and set a $10.00 target price on shares of Gain Therapeutics in a research report on Friday, December 19th. HC Wainwright reiterated a “buy” rating and set a $8.00 price objective on shares of Gain Therapeutics in a research note on Friday, December 19th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Gain Therapeutics in a research report on Monday, December 29th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC grew its stake in Gain Therapeutics by 2.9% during the 2nd quarter. Geode Capital Management LLC now owns 290,462 shares of the company’s stock valued at $523,000 after purchasing an additional 8,251 shares during the last quarter. Sprott Inc. purchased a new position in shares of Gain Therapeutics in the fourth quarter worth about $39,000. Benedict Financial Advisors Inc. lifted its holdings in shares of Gain Therapeutics by 55.6% during the third quarter. Benedict Financial Advisors Inc. now owns 35,000 shares of the company’s stock worth $62,000 after purchasing an additional 12,500 shares during the period. Commonwealth Equity Services LLC purchased a new stake in Gain Therapeutics in the fourth quarter valued at approximately $41,000. Finally, Millennium Management LLC purchased a new stake in shares of Gain Therapeutics in the 4th quarter valued at $45,000. 11.97% of the stock is currently owned by hedge funds and other institutional investors.

Gain Therapeutics Stock Performance

Shares of Gain Therapeutics stock opened at $2.62 on Wednesday. The company has a current ratio of 2.52, a quick ratio of 2.52 and a debt-to-equity ratio of 0.05. The stock’s fifty day moving average price is $2.17 and its 200-day moving average price is $2.37. The firm has a market cap of $100.77 million, a P/E ratio of -4.30 and a beta of -0.03. Gain Therapeutics has a 12 month low of $1.41 and a 12 month high of $4.34.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.